BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

11:17 AM
Sep 27, 2017
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML); prostate cancer

In vitro, cell culture and mouse studies identified two dihydropyrazolopyridine-based dual CREBBP/EP300 inhibitors that could help treat AML and prostate cancer. Chemical synthesis and in vitro binding assays of methylpyrazole-dihydropyrazolopyridine analogs yielded two compounds: GNE-781, which bound CREBBP and EP300 with IC50...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >